• This record comes from PubMed

A novel type of retinoic acid response element in the second intron of the mouse H2Kb gene is activated by the RAR/RXR heterodimer

. 1996 Feb 15 ; 24 (4) : 694-701.

Language English Country Great Britain, England Media print

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/pmid08604312

We have identified and characterized a novel retinoic acid (RA) response element (Hi-RARE) in the second intron of the mouse major histocompatibility H2Kb gene. The Hi-RARE sequence is conserved in all mouse classical and Q class 1 genes, in MHC class 1 genes of the rat, Rhesus macaque, cat and in the vast majority of human classical and non-classical class 1 genes. The Hi-RARE sequence lies within a regulatory element responsible for constitutive expression of a 5' enhancerless H2Kb gene in the Ltk-fibroblasts. Hi-RARE consists of two inverted palindromic RARE consensus sites (5'-PuGGTCA-3') separated by an 8 nt spacer. Mutational analysis revealed that both inverted palindromic hexanucleotide motifs are indispensable functional sites for the 9-cis RA response. The Hi-RARE sequence confers 9-cis RA inducibility to a heterologous promoter. The inducibility is further augmented in embryonal carcinoma cells by the expression of recombinant retinoic acid receptors (PARs) and the retinoid X receptors (RXRs). In vitro, the recombinant RAR/RXR heterodimer creates DNA-protein complex with the Hi-RARE sequence. Treatment of P19 embryonal carcinoma cells with 9C-RA induces the Hi-RARE binding activity of nuclear proteins that proved to be RAR (or RAR-Like)/RXR heterodimer. Thus the Hi-RARE represents a new type of RA response element with a role in the modulation of the expression of MHC class 1 family genes.

See more in PubMed

Adv Immunol. 1979;27:51-177 PubMed

Genes Dev. 1994 Dec 15;8(24):3068-79 PubMed

Nature. 1981 Jun 11;291(5815):455-60 PubMed

Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 PubMed

Cell. 1984 Jan;36(1):139-44 PubMed

Nature. 1984 Aug 2-8;310(5976):415-8 PubMed

Immunogenetics. 1985;21(1):71-82 PubMed

J Immunol. 1985 Sep;135(3):2167-75 PubMed

Cell. 1986 Jan 31;44(2):261-72 PubMed

EMBO J. 1985 Dec 1;4(12):3203-7 PubMed

Proc Natl Acad Sci U S A. 1987 May;84(10):3380-4 PubMed

J Biol Chem. 1988 May 25;263(15):7055-9 PubMed

J Biol Chem. 1989 Jan 5;264(1):178-82 PubMed

J Mol Evol. 1989 Apr;28(4):306-12 PubMed

Nature. 1989 Jun 29;339(6227):714-7 PubMed

Immunogenetics. 1989;30(5):330-4 PubMed

EMBO J. 1989 Sep;8(9):2543-50 PubMed

Mol Cell Biol. 1990 Jan;10(1):243-53 PubMed

Nature. 1990 Jan 11;343(6254):177-80 PubMed

Cell. 1990 May 4;61(3):505-14 PubMed

Immunogenetics. 1990;31(5-6):405-9 PubMed

Immunol Today. 1990 Aug;11(8):286-92 PubMed

Immunogenetics. 1991;33(3):213-5 PubMed

Crit Rev Immunol. 1990;10(3):235-57 PubMed

Comput Appl Biosci. 1991 Apr;7(2):203-6 PubMed

Cell. 1991 Aug 9;66(3):555-61 PubMed

Cell. 1991 Dec 20;67(6):1251-66 PubMed

Cell. 1992 Jan 24;68(2):397-406 PubMed

Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):937-41 PubMed

Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1448-52 PubMed

EMBO J. 1992 Mar;11(3):1003-13 PubMed

Genes Dev. 1992 Mar;6(3):329-44 PubMed

EMBO J. 1992 Apr;11(4):1419-35 PubMed

J Immunol. 1992 Jul 15;149(2):429-37 PubMed

J Immunol. 1992 Sep 15;149(6):1947-56 PubMed

J Biol Chem. 1992 Oct 5;267(28):20264-9 PubMed

EMBO J. 1992 Dec;11(12):4591-600 PubMed

Trends Biochem Sci. 1992 Oct;17(10):427-33 PubMed

Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4 PubMed

Genes Dev. 1993 Feb;7(2):295-307 PubMed

Nature. 1993 Feb 18;361(6413):657-60 PubMed

J Immunol. 1993 Apr 1;150(7):2805-13 PubMed

Mol Cell Biol. 1993 Aug;13(8):5057-69 PubMed

Proc Soc Exp Biol Med. 1993 Sep;203(4):405-17 PubMed

Mol Cell Biol. 1993 Oct;13(10):6157-69 PubMed

EMBO J. 1993 Dec 15;12(13):5029-41 PubMed

Gene. 1993 Dec 15;135(1-2):223-8 PubMed

Genes Dev. 1994 May 1;8(9):1007-18 PubMed

Methods Enzymol. 1980;65(1):499-560 PubMed

Find record

Citation metrics

Logged in users only

Archiving options